Program
Dronabinol
Also written as “Dronabinol Oral Solution”, “GW-2000-02” and “SP-104”.
Its studies are mostly in Pain · Fasting · Vomiting · Sleep Apnea, Obstructive · Cancer Pain, led by 14 companies.
Drug pageDronabinol: every studyMany companies study it; this page follows only the 20 they lead. All 183 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| INSYS Therapeuticsits history only | 30 open or running | phase 1since Oct 5, 2011 | Oct 5, 2011 | none ahead |
| Jazz Pharmaceuticalsits history only | 30 open or running | phase 3since Apr 28, 2008 | Apr 28, 2008 | none ahead |
| Abbottits history only | 20 open or running | phase 3since Mar 21, 2008 | Mar 21, 2008 | none ahead |
| Scilex Pharmaceuticalsits history only | 20 open or running | phase 1since Jul 6, 2021 | Jul 6, 2021 | none ahead |
| Benuvia Therapeuticsits history only | 11 open or running | phase 3since Feb 11, 2026 | Feb 11, 2026 | May 30, 2028phase 3 · NCT07422311 |
| Bionorica Researchits history only | 10 open or running | phase 3since Aug 13, 2009 | Aug 13, 2009 | none ahead |
| CannaXanits history only | 10 open or running | phase 1since Feb 24, 2022 | Feb 24, 2022 | none ahead |
| Daisy Pharma Opioid Ventureits history only | 10 open or running | phase 2since Nov 30, 2018 | Nov 30, 2018 | none ahead |
| FG Brasil LTDAits history only | 10 open or running | phase 3since Mar 8, 2022 | Mar 8, 2022 | none ahead |
| Incannex Healthcareits history only | 11 open or running | phase 2since Jun 3, 2026 | Jun 3, 2026 | Apr 2027phase 2 · NCT07635563 |
| Par Healthits history only | 10 open or running | phase 1since Jun 16, 2011 | Jun 16, 2011 | none ahead |
| SciSparcits history only | 10 open or running | phase 2since Aug 9, 2018 | Aug 9, 2018 | none ahead |
| Sobereyeits history only | 10 open or running | no phasesince Apr 14, 2025 | Apr 14, 2025 | none ahead |
| ZYUS Life Sciencesits history only | 10 open or running | phase 2since Jul 25, 2024 | Jul 25, 2024 | none ahead |
Also a collaborator on its studies: KGK Science and FGK Clinical Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Mar 21, 2008.
- Oct 5, 2011INSYS Therapeutics’ first study: phase 1 study in FastingNew to INSYS TherapeuticsINSYS Therapeutics · NCT01448772 · 88 enrolled · United States
- May 23, 2012Phase 3 study in PainJazz Pharmaceuticals · NCT01606189 · 48 enrolled · United Kingdom
- Mar 14, 2014Phase 1 study in Substance-Related DisordersINSYS Therapeutics · NCT02094599 · 43 enrolled · Canada
- Nov 12, 2015No phase study in HealthyINSYS Therapeutics · NCT02604992 · 54 enrolled · United States
- Aug 9, 2018SciSparc’s first study: phase 2 study in Tourette SyndromeNew to SciSparcSciSparc · NCT03651726 · 60 enrolled · Germany
- Nov 30, 2018Daisy Pharma Opioid Venture’s first study: phase 2 study in Chronic PainNew to Daisy Pharma Opioid VentureDaisy Pharma Opioid Venture · NCT03766269 · 280 enrolled · United States
- Jul 6, 2021Scilex Pharmaceuticals’ first study: phase 1 study in Healthy VolunteersNew to Scilex PharmaceuticalsScilex Pharmaceuticals · NCT04958876 · 52 enrolled · New Zealand
- Aug 5, 2021Phase 1 study in HealthyScilex Pharmaceuticals · NCT05002946 · 18 enrolled · New Zealand
- Feb 24, 2022CannaXan’s first study: phase 1 study in Marijuana AbuseNew to CannaXanCannaXan · NCT05267769 · 12 enrolled · Germany
- Mar 8, 2022FG Brasil LTDA’s first study: phase 3 study in FibromyalgiaNew to FG Brasil LTDAFG Brasil LTDA · NCT05283161 · 40 enrolled
- Jul 25, 2024ZYUS Life Sciences’ first study: phase 2 study in Cancer PainNew to ZYUS Life SciencesZYUS Life Sciences · NCT06533657 · 11 enrolled · Canada
- Apr 14, 2025Sobereye’s first study: no phase study in Cannabis IntoxicationNew to SobereyeSobereye · NCT06967051 · 20 enrolled · Canada
- Feb 11, 2026Benuvia Therapeutics’ first study: phase 3 study in Aberrant Motor Behavior in DementiaNew to Benuvia TherapeuticsBenuvia Therapeutics · NCT07422311 · 140 planned · Australia
- Jun 3, 2026Incannex Healthcare’s first study: phase 2 study in Sleep Apnea, ObstructiveNew to Incannex HealthcareIncannex Healthcare · NCT07635563 · 120 planned · United States
Ahead
- Apr 2027Primary completion: phase 2 study in Sleep Apnea, ObstructiveIncannex Healthcare · NCT07635563
- May 30, 2028Primary completion: phase 3 study in Aberrant Motor Behavior in DementiaBenuvia Therapeutics · NCT07422311
TargetBeta
“Cannabinoid CB1 receptor agonist”ChEMBL 37, by rule
Other programs on CNR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Cannabidiolrule | Jazz Pharmaceuticals | phase 4 | 68 |
| Rimonabantrule | Sanofi | phase 3 | 39 |
| CRB-913rule | corbus-pharmaceuticals-inc | phase 1 | 1 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07635563Sleep Apnea, Obstructive · United States | 2 | Recruiting | Incannex Healthcare | Apr 2027 | 120 |
| NCT07422311Aberrant Motor Behavior in Dementia · Australia | 3 | Not yet recruiting | Benuvia Therapeutics | May 30, 2028 | 140 |
| NCT06967051Cannabis Intoxication · Canada | – | Completed | Sobereye | Aug 19, 2025 | 20 |
| NCT06533657Cancer Pain · Canada | 2 | Completed | ZYUS Life Sciences | Apr 15, 2026 | 11 |
| NCT05283161Fibromyalgia | 3 | UNKNOWN | FG Brasil LTDA | Aug 20, 2022 | 40 |
| NCT05267769Marijuana Abuse · Germany | 1 | Completed | CannaXan | Apr 3, 2022 | 12 |
| NCT05002946Healthy · New Zealand | 1 | Completed | Scilex Pharmaceuticals | Apr 24, 2022 | 18 |
| NCT04958876Healthy Volunteers · New Zealand | 1 | Completed | Scilex Pharmaceuticals | Dec 20, 2021 | 52 |
| NCT03766269Chronic Pain · United States | 2 | UNKNOWN | Daisy Pharma Opioid Venture | Jun 1, 2019 | 280 |
| NCT03651726Tourette Syndrome · Germany | 2 | UNKNOWN | SciSparc | Nov 2019 | 60 |
| NCT02604992Healthy · United States | – | Completed | INSYS Therapeutics | Dec 2015 | 54 |
| NCT02094599Substance-Related Disorders · Canada | 1 | Completed | INSYS Therapeutics | May 2014 | 43 |
| NCT01606189Pain · United Kingdom | 3 | Completed | Jazz Pharmaceuticals | Sep 2002 | 48 |
| NCT01448772Fasting · United States | 1 | Completed | INSYS Therapeutics | Dec 2011 | 88 |
| NCT01380457Fasting · United States | 1 | Completed | Par Health | Apr 2006 | 69 |
| NCT00959218Multiple Sclerosis · Germany | 3 | Completed | Bionorica Research | Mar 2010 | 240 |
| NCT00675948Pain · United Kingdom | 3 | Completed | Jazz Pharmaceuticals | Sep 2006 | 43 |
| NCT00674609Pain · United Kingdom | 3 | Completed | Jazz Pharmaceuticals | Feb 2004 | 177 |
| NCT00642512Vomiting · United States | 3 | Completed | Abbott | Jul 2004 | 64 |
| NCT00642499Vomiting · United States | 2 | Completed | Abbott | Apr 2005 | 103 |
How it is read
Names in the registry
- “Dronabinol”, 4 entries
- “Dronabinol Oral Solution”, 2 entries
- “GW-2000-02”, 2 entries
- “SP-104”, 2 entries
- “IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide”, 1 entry
Codes read as this program: GW200002.
Conditions, from the studies’ own filings
- Pain, 3 studies
- Fasting, 2 studies
- Vomiting, 2 studies
- Sleep Apnea, Obstructive, 1 study
- Cancer Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.